MiMedx Group, Inc $MDXG Stake Boosted by Jacobi Capital Management LLC

Jacobi Capital Management LLC boosted its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 24.6% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,725 shares of the company’s stock after buying an additional 7,250 shares during the period. Jacobi Capital Management LLC’s holdings in MiMedx Group were worth $279,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OneDigital Investment Advisors LLC raised its position in MiMedx Group by 3.9% in the first quarter. OneDigital Investment Advisors LLC now owns 55,157 shares of the company’s stock worth $419,000 after acquiring an additional 2,056 shares in the last quarter. Rhumbline Advisers raised its position in MiMedx Group by 1.4% in the first quarter. Rhumbline Advisers now owns 177,156 shares of the company’s stock worth $1,346,000 after acquiring an additional 2,436 shares in the last quarter. Isthmus Partners LLC raised its position in MiMedx Group by 1.1% in the first quarter. Isthmus Partners LLC now owns 310,262 shares of the company’s stock worth $2,358,000 after acquiring an additional 3,455 shares in the last quarter. Virtus Fund Advisers LLC bought a new stake in MiMedx Group in the fourth quarter worth about $35,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after acquiring an additional 4,049 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen upgraded MiMedx Group from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 2nd. Cantor Fitzgerald boosted their price target on MiMedx Group from $11.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, MiMedx Group has an average rating of “Buy” and a consensus price target of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG opened at $6.94 on Friday. The business has a fifty day simple moving average of $6.98 and a 200 day simple moving average of $6.96. The company has a current ratio of 4.39, a quick ratio of 3.90 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of 33.05 and a beta of 1.74. MiMedx Group, Inc has a one year low of $5.47 and a one year high of $10.14.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, July 30th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.04. The business had revenue of $98.61 million during the quarter, compared to analyst estimates of $90.79 million. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%. Sell-side analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.